No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CAPR240517C5000
- 0.50
- -0.25-33.33%
15min DelayClose May 10 15:58 ET
0.80High0.50Low
0.80Open0.75Pre Close75 Volume247 Open Interest5.00Strike Price5.40KTurnover160.78%IV5.66%PremiumMay 17, 2024Expiry Date0.30Intrinsic Value100Multiplier6DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type0.6505Delta0.3323Gamma8.83Leverage Ratio-0.0348Theta0.0005Rho5.75Eff Leverage0.0026Vega
Intraday
- 5D
- 1D
News
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO, May 09, 2024
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics Updates on Duchenne Treatment Progress
Comments
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
1
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
$Capricor Therapeutics(CAPR.US$ we'll. see $5.34 soon.
1
Investors' expectations of limited future growth may be causing the low P/S ratio. These conditions form a barrier for the share price unless improved. Consider other vital risk factors before investing in Capricor Therapeutics.
$Capricor Therapeutics(CAPR.US$Moomoo 24/7· just. Capricor Therapeutics Receives First Milestone Payment Of $10M From Nippon Shinyaku, Co. Under Exclusive Commercialization And Distribution Agreement![]()
Read more
TrytosaveabitOP : Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla